Medtech start-up raises US$3.5m to improve maternal health outcomes

The women’s health medtech start-up Biorithm has secured US$3.5m in funding to advance maternal care and improve health outcomes for mothers and babies.

Biorithm, which creates solutions for personalised connected maternity care, is developing a remote maternal-foetal care platform to help clinicians identify early signs of complication.

The funding, co-led by Adaptive Capital Partners and SEEDS Capital, is hoped to help the company expand in Southeast Asia and the United States and improve its platform.

Some of the funds will go towards completing clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration.

Amrish Nair, founder and CEO of Biorithm, said: “We are truly heartened to have the support of our new and existing investors. We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications.

“There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with others.

“The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey.”

Julian Robinson, chairman of Biorithm medical advisory board, said: “Biorithm will enhance care, minimise inconvenience, and reduce cost for patients and improve the efficiency and effectiveness of the clinical health care provider. Above all, it will improve medical outcomes for mothers and their babies.”

Shi Ying, founder and managing partner at Adaptive Capital Partners, said: “Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments.

“We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey.”

Tan Kaixin, general manager at SEEDS Capital, added: “By leveraging technology to enable remote monitoring, Biorithm’s offering provides enhanced access to quality care for expectant mothers.

“We are excited to continue backing Biorithm as they accelerate their commercialisation in the US and support their vision of revolutionising the global maternal health market. Investments in medtech start-ups like Biorithm will propel the healthcare ecosystem to new heights.”